๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

2110 Porfiromycin as an adjunct to radiation therapy in squamous cell carcinoma of the head and neck

โœ Scribed by Bruce G. Haffty; Yung H. Son; Rose Papac; Diana Fischer; Lynn D. Wilson; Sara Rockwell; Alan C. Sartorelli; Clarence Sasaki; James J. Fischer

Book ID
108437023
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
162 KB
Volume
36
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Bioreductive alkylating agent porfiromyc
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
โœ Bruce G. Haffty; Yung H. Son; Lynn D. Wilson; Rose Papac; Diana Fischer; Sara Ro ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 141 KB ๐Ÿ‘ 3 views

Porfiromycin (methyl mitomycin C) has been shown in laboratory studies to have increased preferential cytotoxicity to hypoxic cells and therefore may provide enhanced therapeutic efficacy over mitomycin C when used in combination with radiation therapy (RT). The purpose of the two clinical studies r

Targeted therapies in squamous cell carc
Targeted therapies in squamous cell carcinoma of the head and neck
โœ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB ๐Ÿ‘ 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r